The STAR Market has firmly established itself as the listing destination for the world's third-largest biomedical enterprises, trailing only the United States and Hong Kong, China. It has successfully channeled financing to over 30 innovative pharmaceutical enterprises, bolstering their sustained and substantial R&D investments. This, in turn, has catalyzed the rapid advancement of domestic innovative drugs and consistently set new benchmarks for overseas transactions.